Sustainment of Hydroxyurea Adherence in Patients With Sickle Cell Disease - Takeaways - MDSpire

Sustainment of Hydroxyurea Adherence in Patients With Sickle Cell Disease

  • By

  • Andrew M. Heitzer

  • Zachary Wooten

  • Guangjin Luo

  • Marsha Treadwell

  • Allison A. King

  • Victor R. Gordeuk

  • Nirmish Shah

  • Christina M. Abrams

  • Sarah McCuskee

  • Siera Gollan

  • Jennifer Longoria

  • Jane S. Hankins

  • Sickle Cell Disease Implementation Consortium

  • May 6, 2026

  • 0 min

Share

  • 1

    Sickle cell disease affects approximately 100,000 individuals in the US, with hydroxyurea as the primary disease-modifying treatment.

  • 2

    Hydroxyurea use is under 50% among patients with HbSS/HbSb0-thalassemia, partly due to low prescription rates and adherence.

  • 3

    Nonadherence to hydroxyurea is linked to negative outcomes, including increased hospitalizations, pain, and depression.

  • 4

    The Sickle Cell Disease Implementation Consortium enrolled participants to study hydroxyurea use and adherence over four years.

  • 5

    Factors influencing hydroxyurea adherence include age, socioeconomic status, and condition-related issues, with young adults showing significant declines.

Original Source(s)

Sustainment of Hydroxyurea Adherence in Patients With Sickle Cell Disease

  • by Andrew M. Heitzer, Zachary Wooten, Guangjin Luo, Marsha Treadwell, Allison A. King, Victor R. Gordeuk, Nirmish Shah, Christina M. Abrams, Sarah McCuskee, Siera Gollan, Jennifer Longoria, Jane S. Hankins, Sickle Cell Disease Implementation Consortium

  • May 6, 2026

Related Content

Multidimensional assessment of fatigue in patients with brain metastases before and after Gamma Knife radiosurgery

Hims’ Super Bowl fallout, and the FDA reverses course

The 51st Annual Meeting of the European Society for Blood and Marrow Transplantation: Psychiatry and Psychology Group – Poster Session (910–918)

  • November 5, 2025